Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma

F Amant, A De Knijf, B Van Calster, K Leunen, P Neven, P Berteloot, I Vergote, S Van Huffel, P Moerman, F Amant, A De Knijf, B Van Calster, K Leunen, P Neven, P Berteloot, I Vergote, S Van Huffel, P Moerman

Abstract

The objective of this study is to assess the therapeutic importance of surgical castration, adjuvant hormonal treatment and lymphadenectomy in endometrial stromal sarcoma (ESS). A retrospective and multicentric search was performed. Clinicopathologic data were retrieved from cases that were confirmed to be ESS after central pathology review. The protocol was approved by the Ethical Committee. ESS was confirmed histopathologically in 34 women, but follow-up data were available in only 31 women. Surgical treatment (n=31) included hysterectomy with or without bilateral salpingo-oophorectomy (BSO) in 23 out of 31 (74%) and 8 out of 31 (26%) cases, respectively. Debulking surgery was performed in 6 out of 31 cases (19%). Stage distribution was as follows: 22 stage I, 4 stage III and 5 stage IV. Women with stage I disease recurred in 4 out of 22 (18%) cases. Among stage I women undergoing hormonal treatment with or without BSO, 3 out of 15 (20%) and 1 out of 7 (14%) relapsed, respectively. Among stages III-IV women receiving adjuvant hormonal treatment or not, 1 out of 5 (20%) and 3 out of 4 (75%) relapsed, respectively (differences=55.0%, 95% CI=-6.8-81.2%). Kaplan-Meier curves show comparable recurrence rates for stage I disease without adjuvant hormonal treatment when compared to stages III-IV disease treated with surgery and adjuvant hormonal treatment. Furthermore, women taking hormones at diagnosis have a better outcome when compared to women not taking hormonal treatment. Three out of 31 (9%) patients had a systematic lymphadenectomy whereas 3 out of 31 (9%) had a lymph node sampling. In one case, obvious nodal disease was encountered at presentation. Isolated retroperitoneal recurrence occurred in 1 out of 31 (3%) of all cases and in 1 out of 8 (13%) recurrences. This single woman later also developed lung and abdominal metastases. Leaving lymph nodes in situ does not appear to alter the clinical outcome of ESS. Although numbers are low, the retrospective data suggest that the need for surgical castration (BSO) in premenopausal women with early-stage disease should be discussed with the patient on an individual basis. The data support the current practice in some centres to administer adjuvant hormonal treatment.

Figures

Figure 1
Figure 1
Kaplan–Meier plots show the estimated probability of recurrence in function of adjuvant hormonal treatment, type of surgery and stage.
Figure 2
Figure 2
Kaplan–Meier plots show the estimated probability of survival in function of type of adjuvant hormonal treatment, type of surgery and stage.

References

    1. Amant F, Moerman P, Cadron I, Neven P, Berteloot P, Vergote I (2003) The diagnostic problem of endometrial stromal sarcoma: report on 6 cases. Gynecol Oncol 90: 37–43
    1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I (2005) Endometrial cancer. Lancet 366: 491–505
    1. Amant F, Moerman P, Vergote I (2004a) The classification of a uterine sarcoma as ‘high-grade endometrial stromal sarcoma’ should be abandoned. Gynecol Oncol 95: 412–413
    1. Amant F, Schurmans K, Steenkiste E, Verbist L, Abeler V, Tulunay G, de Jonge E, Massuger L, Moerman P, Vergote I (2004b) Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma. Gynecol Oncol 93: 680–685
    1. Beer TW, Buchanan R, Buckley CH (1995) Uterine stromal sarcoma following tamoxifen treatment. J Clin Pathol 48: 596
    1. Burke C, Hickey K (2004) Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue. Obstet Gynecol 104: 1182–1184
    1. Chang K, Crabtree G, Lim-Tan S, Kempson R, Hendrickson M (1990) Primary uterine endometrial stromal neoplasms. Am J Surg Pathol 14: 415–439
    1. Chu M, Mor G, Lim C, Zheng W, Parkash V, Schwartz P (2003) Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol 90: 170–176
    1. Clement P, Scully R (1974) Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of ten cases of a distinctive type of Mullerian mixed tumor. Cancer 34: 1138–1149
    1. Clement P, Scully R (1990) Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol 21: 363–381
    1. Evans H (1982) Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma. Cancer 50: 2170–2182
    1. Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Urgesi A, Lissoni A, Losa G, Fanucchi A (1996) Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol 63: 247–253
    1. Gloor E, Schnyder P, Cikes M, Hofstetter J, Cordy R, Burnier K (1982) Endolymphatic stromal myosis: surgical and hormonal treatment of extensive abdominal recurrence 20 years after hysterectomy. Cancer 50: 1888–1889
    1. Hart W, Yoonnessi M (1977) Endometrial stromatosis of the uterus. Obstet Gynecol 49: 393–403
    1. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
    1. Leunen K, Amant F, Debiec-Rychter M, Croes R, Hagemeijer A, Schoenmakers E, Vergote I (2003) Endometrial stromal sarcoma presenting as postpartum haemorrhage: report of a case with a sole t(10;17)(q22;p13) translocation. Gynecol Oncol 91: 265–271
    1. Leunen M, Breugelmans H, De Sutter Ph, Bourgain C, Amy JJ (2004) Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor Letrozole. Gynecol Oncol 95: 769–771
    1. Li A, Giuntoli R, Drake R, Byun S, Rojas F, Barbuto D, Klipfel N, Edmonds P, Miller D, Karlan B (2005) Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet Gynecol 106: 1304–1308
    1. Maluf F, Sabbatini P, Schwartz L, Xia F, Aghajanian C (2001) Endometrial stromal sarcoma: objective response to letrozole. Gynecol Oncol 82: 384–388
    1. Newcombe RG (1998) Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 17: 873–890
    1. Oliva E, Clement P, Young R (2000) Endometrial stromal tumors: an update on a group of tumors with a protean phenotype. Adv Anat Pathol 7: 257–281
    1. Pink D, Lindner T, Mrozek A, Kretzschmar A, Thuss-Patience P, Dörken B, Reichardt P (2006) Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol 101: 464–469
    1. Reich O, Regauer S, Urdl W, Lahousen M, Winter R (2000) Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas. Br J Cancer 82: 1030–1034
    1. Reich O, Winter R, Regauer S (2005) Should lymphadenectomy be performed in patients with endometrial stromal sarcoma? Gynecol Oncol 97: 982.
    1. Riopel J, Plante M, Renaud M, Roy M, Têtu B (2005) Lymph node metastases in low-grade endometrial stromal sarcoma. Gynecol Oncol 96: 402–406
    1. Sterne JA, Davey Smith G (2001) Sifting the evidence – what's wrong with significance tests. BMJ 322: 226–231

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren